gefitinib — United Healthcare

Initial criteria

• Diagnosis of central nervous system (CNS) cancer with metastatic lesions
• Iressa is active against primary (NSCLC) tumor with a known EGFR sensitizing mutation

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Iressa therapy

Approval duration

12 months